Results 91 to 100 of about 2,004 (157)

Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial. [PDF]

Mult Scler
Bennett JL, Bhattacharyya S, Zabeti A, Levy M, de Sèze J, Taney MJ, Parks B, Allen K, Akpoji U, Pittock SJ.   +9 more
europepmc   +1 more source

Complement C5 inhibition with eculizumab or ravulizumab is associated with increased cardiovascular and thromboembolic risk after ST-elevation myocardial infarction: a propensity-matched global retrospective cohort study. [PDF]

BMC Cardiovasc Disord
Vahldieck C.
europepmc   +1 more source

Comparative Efficacy of Complement Inhibitors in Complement Inhibitor-Naïve PNH: A Systematic Review With Supportive Exploratory Network Meta-Analysis of Randomized Trials. [PDF]

EJHaem
Ishaque R, Talpur AS, Sidra H, Memon H, Memon FT, Talat F, Rafiq T, Rayamajhi S.   +7 more
europepmc   +1 more source

Complement Inhibition Therapy in Myasthenic Crisis-A Multicentre Retrospective Analysis of 17 Cases From Germany. [PDF]

Eur J Neurol
Gerischer L, Stein M, Schneider A, Tangen H, Loris J, Glaubitz S, Zschüntzsch J, Oy UH, Schubert C, Heesen C, Schlag M, Hagenacker T, Oeztuerk M, Ruck T, Doksani P, Dusemund C, Herdick M, Herzig-Nichtweiß J, Mergenthaler P, Stascheit F, Suboh A, Schwarz L, Hoffmann S, Meisel A, Lehnerer S.   +24 more
europepmc   +1 more source

Ravulizumab in NMOSD with associated interstitial pneumonitis in a 59-year-old female patient: a case report. [PDF]

Front Immunol
Neundorf A, Dittrich R.
europepmc   +1 more source

Beyond Vaccination: Persistent Meningococcal Risk in Anti-C5-Treated aHUS-Case Report and Review of Literature. [PDF]

J Clin Med
Matarese S, Brisca G, Moscatelli A, Romanengo M, Mesini A, Mariani M, Mortari G, Castagnola E, Gentile M, Verrina E, Ardissino G, La Porta E.   +11 more
europepmc   +1 more source

Optimizing Care in Patients with Paroxysmal Nocturnal Hemoglobinuria: Managing Suboptimal Response and Uncontrolled Disease. [PDF]

J Blood Med
Bienz M, Oliver M, Sperlich C, Patriquin CJ.   +3 more
europepmc   +1 more source

Assessing the Value Contribution of Vyvgart^® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis. [PDF]

Adv Ther
Cortés-Vicente E, Guerrero A, Díaz C, Martínez E, Toja-Camba FJ, Abad MR, Serra JM, Trillo JL, Martín Machín C, Gil A.   +9 more
europepmc   +1 more source

C3 mutation-associated atypical hemolytic uremic syndrome with severe renal dysfunction and hypertensive emergency successfully treated with ravulizumab and sacubitril/valsartan: a case report. [PDF]

BMC Nephrol
Yanagidani H, Maeoka Y, Yoshida M, Ueda M, Kumano M, Takahashi A, Okubo A, Kato N, Maruyama S, Masaki T.   +9 more
europepmc   +1 more source

Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA. [PDF]

Neurol Ther
Saccà F, Lee J, Yee KS, Silvestri NJ, Sabatella G.   +4 more
europepmc   +1 more source